TITLE

OTHER NEWS TO NOTE

PUB. DATE
January 2009
SOURCE
BioWorld Today;1/30/2009, Vol. 20 Issue 19, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on the biopharmaceutical industry. The European Union (EU) has approved the use of Zavesca from Actelion Ltd. in treating progressive neurological manifestations of Niemann-Picktype C disease. Alexion Pharmaceuticals Inc. has announced that Health Canada approved the use Soliris for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Gen-Probe Inc. and Chiron have extended their collaboration for the development of molecular technologies for blood screening.
ACCESSION #
36350912

 

Related Articles

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates.  // Bioworld Week;7/25/2011, Vol. 19 Issue 30, p5 

    The article reports on the slow sales trend of drug Soliris (eculizumab) manufactured by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut for the treatment of paroxysmal nocturnal hemoglobinuria.

  • Alexion, Others Show Resilience After Breakouts. KEN SHREVE // Investors Business Daily;12/3/2014, pB08 

    Stocks that show resilience and trade tightly after a are worth watching. Why? Because price action like this can often a new entry after an initial breakout.

  • EARNINGS ROUNDUP.  // BioWorld Today;10/27/2008, Vol. 19 Issue 209, p3 

    The article reports that Alexion Pharmaceuticals Inc. of Cheshire, Connecticut reported total revenue of $76.5 million for the third quarter of 2008. According to the article, this came from sales of paroxysmal nocturnal hemoglobinuria drug Soliris which were up from the $21.8 milion in revenues...

  • Alexion Reports 3rd Qtr 2011 Results.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p841 

    The article reports on the announcement of Alexion Pharmaceuticals Inc. for its financial results for the 3 and 9 months that ended September 30, 2011 in Cheshire, Connecticut. The company has reported 204.0 million U.S. dollar total revenues in the third quarter of 2010 from net product sales...

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates. Boggs, Jennifer // BioWorld Today;7/22/2011, Vol. 22 Issue 141, p1 

    The article reports on the second quarter earnings of Alexion Pharmaceuticals Inc. in 2011, which prompted the company to increase the sales guidance for its paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris. The price of the stocks of the company rose 9 percent on July 21, 2011 to close at...

  • Alexion Gets FDA Nod For Soliris; First Drug For PNH. Boggs, Jennifer // BioWorld Today;3/19/2007, Vol. 18 Issue 53, p1 

    The article reports that the monoclonal antibody product Soliris from Alexion Pharmaceuticals won U.S. Food and Drug Administration approval in paroxysmal nocturnal hemoglobinuria (PNH), making it the first therapy indicated for the rare genetic disorder. The news boosted the shares of Alexion...

  • ASH 2008.  // BioWorld Today;12/9/2008, Vol. 19 Issue 238, p7 

    The article reports on the announcement by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut, that Soliris or eculizumab, a terminal complement inhibitor used in treating paroxysmal nocturnal hemoglobinuria (PNH), was associated with improved hematologic parameters. In one patient with cold...

  • Alexion Joins EURORDIS, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2012.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article informs that Alexion Pharmaceuticals Inc. is celebrating Rare Disease Day 2012 in association with European Organization for Rare Diseases (EURORDIS), the National Organization for Rare Disorders (NORD) Inc. and patient groups. It further informs that Alexion has developed Soliris...

  • TGA approval for Soliris.  // Australian Journal of Pharmacy;Apr2009, Vol. 90 Issue 1067, p39 

    The article reports on the approval of Soliris (eculizumab) by the Therapeutic Goods Administration (TGA) of Australia as treatment for the blood disorder paroxysmal nocturnal haemoglobinuria (PNH).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics